These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 32280965

  • 1. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
    Honap S, Chee D, Chapman TP, Patel M, Kent AJ, Ray S, Sharma E, Kennedy J, Cripps S, Walsh A, Goodhand JR, Ahmad T, Satsangi J, Irving PM, Kennedy NA, LEO [London, Exeter, Oxford] IBD Research Consortium .
    J Crohns Colitis; 2020 Oct 05; 14(10):1385-1393. PubMed ID: 32280965
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
    Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-Biroulet L, Simon M, Viennot S, Bouhnik Y.
    Dig Liver Dis; 2020 Mar 05; 52(3):268-273. PubMed ID: 31732444
    [Abstract] [Full Text] [Related]

  • 6. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.
    Lopes SR, Martins C, Teixeira M, Tomás D.
    World J Gastroenterol; 2024 Sep 14; 30(34):3929-3931. PubMed ID: 39350781
    [Abstract] [Full Text] [Related]

  • 7. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, Niezychowski W.
    Br J Clin Pharmacol; 2018 Jun 14; 84(6):1136-1145. PubMed ID: 29377257
    [Abstract] [Full Text] [Related]

  • 8. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
    Carvalhas Gabrielli AM, Ferretti F, Monico CM, Tombetti E, Maconi G, Romeo S, Piazza O Sed N, Caprioli F, Mazzola AM, Alicante S, Bertè R, Lolli E, Scribano ML, Buscarini E, Ricci C, Carmagnola S, Ardizzone S, Cannatelli R.
    Dig Dis Sci; 2024 May 14; 69(5):1785-1792. PubMed ID: 38530500
    [Abstract] [Full Text] [Related]

  • 9. Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study.
    Yoon H, Ye BD, Kang SB, Lee KM, Choi CH, Jo JY, Woo J, Cheon JH.
    BMC Gastroenterol; 2024 Aug 19; 24(1):273. PubMed ID: 39160459
    [Abstract] [Full Text] [Related]

  • 10. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.
    Kojima K, Watanabe K, Kawai M, Yagi S, Kaku K, Ikenouchi M, Sato T, Kamikozuru K, Yokoyama Y, Takagawa T, Shimizu M, Shinzaki S.
    World J Gastroenterol; 2024 Apr 07; 30(13):1871-1886. PubMed ID: 38659488
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
    Straatmijer T, van Gennep S, Duijvestein M, Ponsioen CIJ, Gecse KB, D'Haens GR, Löwenberg M.
    Eur J Gastroenterol Hepatol; 2021 Oct 01; 33(10):1288-1297. PubMed ID: 33405424
    [Abstract] [Full Text] [Related]

  • 13. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort.
    Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JR.
    Inflamm Bowel Dis; 2024 Oct 03; 30(10):1707-1713. PubMed ID: 37843044
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
    Winthrop KL, Loftus EV, Baumgart DC, Reinisch W, Nduaka CI, Lawendy N, Chan G, Mundayat R, Friedman GS, Salese L, Thorpe AJ, Su C.
    J Crohns Colitis; 2021 Jun 22; 15(6):914-929. PubMed ID: 33245746
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
    Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C.
    Aliment Pharmacol Ther; 2020 Jan 22; 51(2):271-280. PubMed ID: 31660640
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
    Chiorean M, Daperno M, Lees CW, Bonfanti G, Soudis D, Modesto I, Deuring JJ, Edwards RA.
    Adv Ther; 2023 Oct 22; 40(10):4440-4459. PubMed ID: 37525075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.